No Name, The FDA getting trigger happy

[Image]( EMAIL}/redirect Approved! The anti-anti-vaxxers at the FDA loosened the reins this week, giving both Gilead’s remdesivir and Roche’s COVID antibody test the greenlight for “emergency use.” Is a global pandemic not an emergency? That feels a lot like an emergency... Gil-ville Gilead’s remdesivir got the [go-ahead]( as the first medicinal treatment to handle COVID symptoms after early clinical data showed signs of recovery in those treated with the drug. According to the study, the drug reduced the time taken to recover, those given the drug recovered in 11 days, compared to the 15 day standard. Despite the positive results, Gilead can’t go making it rain remdesivir all willy-nilly. Use of the "miracle drug" is limited to those hospitalized with low blood-oxygen levels, and those who need breathing support. Oh, so people who meet the [Ivan Drago standard?]( There was word that this might happen earlier last week, as the FDA teased Gilead, but now that they’ve signed off, it’s clear the FDA means business. Gilead closed down 4.8% on Friday, despite the news. Gilead share prices are up 23% on the year. I wonder why? EMAIL}/redirect EMAIL}/redirect Roche-ing ahead Roche Holding got its antibody test [greenlit]( by the FDA as well. Roche’s test helps identify the antibodies created by humans after they’ve been infected with coronavirus. The key here is that those with minimal symptoms, or those who are asymptomatic, may be identified. These tests are seen as the gateway to understanding the spread of the virus, tracking it, and allowing civilization to open back up. After all, there are only so many frozen pizzas a man can eat... Roche says its test has been 100% accurate in detecting COVID antibodies, and 99.8% accurate in ruling those antibodies out of those who haven’t gotten the virus. Of course, it did. The bottom line... Between a potential treatment and antibody tests, could the “new normal” be on the horizon? Many governments are hoping that antibody testing can be used to identify those whose bodies have already developed a way to fight the virus, and therefore could safely return to the workforce, helping buoy sputtering economies. To do that, some countries are suggesting the use of “[immunity passports]( for those who have a natural defense against the virus. Nope, no potential human rights violations to see here. EMAIL}/redirect EMAIL}/redirect ☑️ Too high. Elon Musk is back on his bullsh*t. The meme lord himself [got his tweetstorm on]( last week, firing off hot takes about selling all of his possessions and raging against the machine. But his most troublesome tweet sent shares down 10% Friday. He stated that $TSLA stock price was too high. I doubt that was approved by his in-house counsel. Tesla’s CEO has gotten into hot water in the past over his infamous “funding secured” tweet in August 2018. He even promised the SEC that he'd get all statements about Tesla’s stock prices and finances approved by legal counsel before firing off a tweet. Despite the drop in share price, sir-memes-a-lot is still within striking distance of his big $730M payday. The electric car's trailing six-month market value [stands at $99.1B]( just $1B shy of the targeted $100B, which would trigger his payout. ☑️ Buh-Bye. Softbank’s international arm [is cutting 10% of its workforce]( (about 24 employees) in an effort to ‘operate more efficiently’ (read: we kinda fudged up with that WeWork investment...ok, fine, Uber too, and now need to cut costs). The conglomerate expects wider net losses, totaling $8.4B for the year ending in March, thanks to, you guessed it, struggles with its WeWork investment. Do you see a theme here? ☑️ Mr. Bezos, c’mon down. Jeffrey Congress, as he’ll soon be dubbed, [has been asked to testify]( before the House of Representatives (f*cking nerd can’t even land a Senate inquiry) in regards to Amazon’s use of third party data. The company has previously stated in DC that it does not utilize such information for a competitive advantage. Sure, and it doesn’t clear browser history when it’s done with the family computer either... [ICYMI]( a WSJ report was released April 23, alleging that Amazon has been using independent third-party data from its sellers to help launch its own products. More than 20 former employees from Amazon’s private-label business, AmazonBasics, revealed that Amazon did, in fact, utilize third party data for such purpose, and now Congress wants to hear from the big cheese himself. ☑️ We’re sick of it. Essential employees of Target, Walmart, Wholefoods, FedEx, and other companies [had a ‘sickout’ on Friday](. Or as I call it, a three-day weekend. They protested the need to work in unsafe conditions where proper safety measures are not implemented. While it’s unclear how many participated at this point, it doesn’t seem like many followed through, based on Target’s statement that ‘these concerns have been raised by a very small minority of the 340k workforce’. But that statement might be one-sided. The effort also asked people to boycott shopping at certain mega-retailers on Friday, International Workers Day, which if I had to guess, only lead to more people going because they thought the stores would be empty. EMAIL}/redirect EMAIL}/redirect To get Exclusive Offers make sure you grab your cellphone (which you are probably doing right now) and join our VIP text messaging list (standard text and messaging rates may apply)to make it even easier, if you are on your cell phone now click this Button Below: [SIGN ME UP NOW]( © 2019 PTE.la PTE, LLC (publisher of PTE.la) is NOT registered as an investment adviser nor a broker/dealer with either the U. S. Securities & Exchange Commission or any state securities regulatory authority. Users of this website are advised that all information presented on this website is solely for informational purposes, is not intended to be used as a personalized investment recommendation, and is not attuned to any specific portfolio or to any user's particular investment needs or objectives. Past performance is NOT indicative of future results. Furthermore, such information is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell (short or otherwise) any security. All users of this website must determine for themselves what specific investments to make or not make and are urged to consult with their own independent financial advisors with respect to any investment decision. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. All opinions, analyses and information included on this website are based on sources believed to be reliable and written in good faith, but should be independently verified, and no representation or warranty of any kind, express or implied, is made, including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. In addition, we undertake no responsibility to notify such opinions, analyses or information or to keep such opinions, analyses or information current. Also be aware that owners, employees and writers of and for PTE, LLC may have long or short positions in securities that may be discussed on this website or newsletter. Past results are not indicative of future profits. This table is accurate, though not every trade is represented. Profits and losses reported are simulated figures from virtual simulated portfolios. We are engaged in the business of advertising and promoting companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. PTE.la’s sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as are commendation by PTE.la or an offer or solicitation to buy or sell any security. Neither the owner of PTE.la nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with alicensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. To review our complete disclaimer and additional information, please visit . PTE.la makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors. PTE.la is owned and operated by PTE LLC. PTE LLC has not been compensated for this specific email, we do have advertisements in this email that we get paid if you click one of the ads (we have not investigated any of the advertisements). Any compensation received by PTE LLC constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. A third party of PTE LLC may have shares and may liquidate, which may negatively affect the stock price. PTE LLC affiliates may at any time have a position in the securities mentioned herein and may increase or decrease such positions without notice which will negatively affect the market. Some of the content in this release contains forward - looking information within the meaning of Section 27 A of the Securities Act of 1 9 9 3 and Section 21 E of the Securities Exchange Act of 1 9 3 4 including statements regarding expected continual growth of the profiled company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company's actual results of operation. A company's actual performance could greatly differ from those described in any forward - looking statements or announcements mentioned in this release. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the Securities and Exchange Commission. However, acompany’s past performance does not guarantee future results. Generally, the information regarding a company profiled is provided from public sources which we believe to be reliable but is not guaranteed by us as being accurate. Further specific financial information, filings and disclosures as well as general investor information about the profiled company, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) website www.sec.gov and the Financial Industry Regulatory Authority (“FINRA”) website at www.finra.org. Any investment should be made only after consulting with a qualified investment advisor and reviewing the publicly available financial statement and other information about the company profiled and verifying that the investment is appropriate and suitable. PTE.la makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained in this release or on our website. PTE Team 9 Downing street Newark NJ 07105 USA [Unsubscribe]( | [Change Subscriber Options](